EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Post-transplant lymphoproliferative disorder mimicking Baló’s concentric sclerosis

Xiaofeng Xiong, Ting Zhang, Yu Li, Hongtao Jin, Xintao Lei, Yanzhen Jiang, Qiaoying Huang, Qianhui Xu, Ying Huang

Frontiers in Oncology · 08.06.2026 · 16

DOI: 10.3389/fonc.2026.1819442 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 08.06.2026. Verfasst von Xiaofeng Xiong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-Transplant Lymphoproliferative Disorder (PTLD) is a lymphoproliferative disease that occurs in recipients of solid organ or hematopoietic stem cell transplants, resulting from the malignant transformation of benign proliferative lymphoid or plasma cell tissue due to immunosuppression. As an immunodeficiency-associated lymphoproliferative disorder, PTLD can affect various organs, including lymph nodes, the gastrointestinal tract, lungs, kidneys, and the central nervous system. The overall prognosis is generally poor. This case report describes a 37-year-old female patient presenting with magnetic resonance imaging (MRI) findings mimicking Baló’s concentric sclerosis (BCS). However, pathological biopsy confirmed a diagnosis of monomorphic Primary Central Nervous System PTLD (PCNS-PTLD). The patient was treated with immunosuppression reduction combined with rituximab plus lenalidomide which led to a partial remission. Both PTLD and Baló’s concentric sclerosis exhibit significant improvement with high-dose corticosteroid therapy, which can complicate the differential diagnosis. This report aims to summarize the clinical features of a case of PCNS-PTLD that mimicked Baló’s concentric sclerosis to enhance the early recognition and diagnosis of PCNS-PTLD.

Schlagwörter

Stichwörter der Autor:innen

Baló’s concentric sclerosisCNSPTLDdifferent diagnosispost-transplant lymphoproliferative disorder

Autor:innen und Institutionen

  • Department of Neurology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.
  • Department of Neurology, The First Affiliated Hospital (Shenzhen People's Hospital), School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  • Department of Neurology, Shenzhen Third People's Hospital, Shenzhen, China.
  • Department of Pathology, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, China.
  • Department of Neurology, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, China.
  • Department of Neurology, Shenzhen Bao'an Shiyan People's Hospital, Shenzhen, China.

Zitieren

APA

Xiong, X., Zhang, T., Li, Y., Jin, H., Lei, X., Jiang, Y., Huang, Q., Xu, Q., & Huang, Y. (2026). Case Report: Post-transplant lymphoproliferative disorder mimicking Baló’s concentric sclerosis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1819442

Vancouver

Xiong X, Zhang T, Li Y, Jin H, Lei X, Jiang Y, et al. Case Report: Post-transplant lymphoproliferative disorder mimicking Baló’s concentric sclerosis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1819442

BibTeX
@article{Xiong2026,
  author = {Xiong, Xiaofeng and Zhang, Ting and Li, Yu and Jin, Hongtao and Lei, Xintao and Jiang, Yanzhen and Huang, Qiaoying and Xu, Qianhui and Huang, Ying},
  title = {Case Report: Post-transplant lymphoproliferative disorder mimicking Baló’s concentric sclerosis},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1819442}
}
Kostenlos starten →